TF - A novel cell-permeable and selective inhibitor of human protein kinase CK2 induces apoptosis in the prostate cancer cell line LNCaP

Biochimica et Biophysica Acta - General Subjects

Volumn 1820, Issue 7, 2012, Pages 970-977

  Götz, Claudia ^a   Gratz, Andreas ^b   Kucklaender, Uwe ^c   Jose, Joachim ^b  

^a SAARLAND UNIVERSITY   (Germany)

^b UNIVERSITY OF MÜNSTER   (Germany)

^c HEINRICH HEINE UNIVERSITY   (Germany)

Author keywords

CK2; Dibenzo b,d furan; Drug discovery; Inhibitor; LNCaP

Indexed keywords

6,7 DICHLORO 1,4 DIHYDRO 8 HYDROXY 4 [(4 METHYLPHENYLAMINO)METHYLEN]DIBENZO[B,D]FURAN 3 (2H) ONE; ANTINEOPLASTIC AGENT; CASEIN KINASE II; PROTEIN SERINE THREONINE KINASE INHIBITOR; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BINDING AFFINITY; CANCER CELL; CELL COUNT; CELL MEMBRANE PERMEABILITY; CELL VIABILITY; CONTROLLED STUDY; DRUG CONCENTRATION; DRUG PROTEIN BINDING; DRUG SCREENING; DRUG SELECTIVITY; DRUG STRUCTURE; ENZYME ACTIVITY; ENZYME INHIBITION; IC 50; INCUBATION TIME; KI; PRIORITY JOURNAL; PROSTATE CANCER;

APOPTOSIS; BENZOFURANS; BLOTTING, WESTERN; CASEIN KINASE II; CELL LINE, TUMOR; CELL SURVIVAL; HUMANS; INHIBITORY CONCENTRATION 50; KINETICS; MALE; PHOSPHORYLATION; PROSTATIC NEOPLASMS; PROTEIN KINASE INHIBITORS; UP-REGULATION;

EID: 84860669088     PISSN: 03044165     EISSN: 18728006     Source Type: Journal    
DOI: 10.1016/j.bbagen.2012.02.009     Document Type: Article

References (45)

1. A.C. Bibby, and D.W. Litchfield The multiple personalities of the regulatory subunit of protein kinase CK2: CK2 dependent and CK2 independent roles reveal a secret identity for CK2beta Int. J. Biol. Sci. 1 2005 67 79
2. D.W. Litchfield Protein kinase CK2: structure, regulation and role in cellular decisions of life and death Biochem. J. 369 2003 1 15
3. K. Ahmed, D.A. Gerber, and C. Cochet Joining the cell survival squad: an emerging role for protein kinase CK2 Trends Cell Biol. 12 2002 226 230
4. K.A. Ahmad, G. Wang, J. Slaton, G. Unger, and K. Ahmed Targeting CK2 for cancer therapy Anticancer Drugs 16 2005 1037 1043
5. R.A. Faust, M. Gapany, P. Tristani, A. Davis, G.L. Adams, and K. Ahmed Elevated protein kinase CK2 activity in chromatin of head and neck tumors: association with malignant transformation Cancer Lett. 101 1996 31 35
6. S. Yenice, A.T. Davis, S.A. Goueli, A. Akdas, C. Limas, and K. Ahmed Nuclear casein kinase 2 (CK-2) activity in human normal, benign hyperplastic, and cancerous prostate Prostate 24 1994 11 16
7. K. Prowald, H. Fischer, and O.G. Issinger Enhanced casein kinase II activity in human tumour cell cultures FEBS Lett. 176 1984 479 483
8. K.A. Ahmad, G. Wang, G. Unger, J. Slaton, and K. Ahmed Protein kinase CK2 - a key suppressor of apoptosis Adv. Enzyme Regul. 48 2008 179 187
9. J.S. Duncan, and D.W. Litchfield Too much of a good thing: the role of protein kinase CK2 in tumorigenesis and prospects for therapeutic inhibition of CK2 Biochim. Biophys. Acta 1784 2008 33 47
10. J.H. Trembley, Z. Chen, G. Unger, J. Slaton, B.T. Kren, W.C. Van, and K. Ahmed Emergence of protein kinase CK2 as a key target in cancer therapy Biofactors 36 2010 187 195
11. S. Sarno, M. Salvi, R. Battistutta, G. Zanotti, and L.A. Pinna Features and potentials of ATP-site directed CK2 inhibitors Biochim. Biophys. Acta 1754 2005 263 270
12. P. Zien, J.S. Duncan, J. Skierski, M. Bretner, D.W. Litchfield, and D. Shugar Tetrabromobenzotriazole (TBBt) and tetrabromobenzimidazole (TBBz) as selective inhibitors of protein kinase CK2: evaluation of their effects on cells and different molecular forms of human CK2 Biochim. Biophys. Acta 1754 2005 271 280
13. S.E. Perea, O. Reyes, Y. Puchades, O. Mendoza, N.S. Vispo, I. Torrens, A. Santos, R. Silva, B. Acevedo, E. Lopez, V. Falcon, and D.F. Alonso Antitumor effect of a novel proapoptotic peptide that impairs the phosphorylation by the protein kinase 2 (casein kinase 2) Cancer Res. 64 2004 7127 7129
14. S.E. Perea, O. Reyes, I. Baladron, Y. Perera, H. Farina, J. Gil, A. Rodriguez, D. Bacardi, J.L. Marcelo, K. Cosme, M. Cruz, C. Valenzuela, P.A. Lopez-Saura, Y. Puchades, J.M. Serrano, O. Mendoza, L. Castellanos, A. Sanchez, L. Betancourt, V. Besada, R. Silva, E. Lopez, V. Falcon, I. Hernandez, M. Solares, A. Santana, A. Diaz, T. Ramos, C. Lopez, J. Ariosa, L.J. Gonzalez, H. Garay, D. Gomez, R. Gomez, D.F. Alonso, H. Sigman, L. Herrera, and B. Acevedo CIGB-300, a novel proapoptotic peptide that impairs the CK2 phosphorylation and exhibits anticancer properties both in vitro and in vivo Mol. Cell. Biochem. 316 2008 163 167
15. S. Sarno, S. Moro, F. Meggio, G. Zagotto, D. Dal Ben, P. Ghisellini, R. Battistutta, G. Zanotti, and L.A. Pinna Toward the rational design of protein kinase casein kinase-2 inhibitors Pharmacol. Ther. 93 2002 159 168
16. Z. Nie, C. Perretta, P. Erickson, S. Margosiak, R. Almassy, J. Lu, A. Averill, K.M. Yager, and S. Chu Structure-based design, synthesis, and study of pyrazolo[1,5-a][1,3,5]triazine derivatives as potent inhibitors of protein kinase CK2 Bioorg. Med. Chem. Lett. 17 2007 4191 4195
17. Z. Nie, C. Perretta, P. Erickson, S. Margosiak, J. Lu, A. Averill, R. Almassy, and S. Chu Structure-based design and synthesis of novel macrocyclic pyrazolo[1,5-a] [1,3,5]triazine compounds as potent inhibitors of protein kinase CK2 and their anticancer activities Bioorg. Med. Chem. Lett. 18 2008 619 623
18. F. Pierre, S.E. O'Brien, M. Haddach, P. Bourbon, M.K. Schwaebe, E. Stefan, L. Darjania, R. Stansfield, C. Ho, A. Siddiqui-Jain, N. Streiner, W.G. Rice, K. Anderes, and D.M. Ryckman Novel potent pyrimido[4,5-c]quinoline inhibitors of protein kinase CK2: SAR and preliminary assessment of their analgesic and anti-viral properties Bioorg. Med. Chem. Lett. 21 2011 1687 1691
19. A. Siddiqui-Jain, D. Drygin, N. Streiner, P. Chua, F. Pierre, S.E. O'Brien, J. Bliesath, M. Omori, N. Huser, C. Ho, C. Proffitt, M.K. Schwaebe, D.M. Ryckman, W.G. Rice, and K. Anderes CX-4945, an orally bioavailable selective inhibitor of protein kinase CK2, inhibits prosurvival and angiogenic signaling and exhibits antitumor efficacy Cancer Res. 70 2010 10288 10298
20. F. Pierre, P.C. Chua, S.E. O'Brien, A. Siddiqui-Jain, P. Bourbon, M. Haddach, J. Michaux, J. Nagasawa, M.K. Schwaebe, E. Stefan, A. Vialettes, J.P. Whitten, T.K. Chen, L. Darjania, R. Stansfield, J. Bliesath, D. Drygin, C. Ho, M. Omori, C. Proffitt, N. Streiner, W.G. Rice, D.M. Ryckman, and K. Anderes Pre-clinical characterization of CX-4945, a potent and selective small molecule inhibitor of CK2 for the treatment of cancer Mol. Cell. Biochem. 356 2011 27 43
21. U. Kuckländer, and H. Töberich Zur Umsetzung von 2-Aminomethylen)cyclohexanon-Derivaten mit Dichlorchinonen Chem. Ber. 116 1983 152 158
22. A. Gratz, C. Götz, and J. Jose A CE-based assay for human protein kinase CK2 activity measurement and inhibitor screening Electrophoresis 31 2010 634 640
23. N. Grankowski, B. Boldyreff, and O.-G. Issinger Isolation and characterization of recombinant human casein kinase II subunits α and β from bacteria Eur. J. Biochem. 198 1991 25 30
24. C.C. Schneider, A. Hessenauer, C. Götz, and M. Montenarh DMAT: an inhibitor of protein kinase CK2 induces reactive oxygen species and DNA double strand breaks Oncol. Rep. 21 2009 1593 1597
25. M. Faust, N. Schuster, and M. Montenarh Specific binding of protein kinase CK2 catalytic subunits to tubulin FEBS Lett. 462 1999 51 56
26. W. Nastainczyk, I. Schmidt-Spaniol, B. Boldyreff, and O.-G. Issinger Isolation and characterization of a monoclonal anti-protein kinase CK2 β-subunit antibody of the IgG class for the direct detection of CK2 β-subunit in tissue cultures of various mammalian species and human tumors Hybridoma 14 1995 335 339
27. W. Nastainczyk, O.G. Issinger, and B. Guerra Epitope analysis of the MAb 1AD9 antibody detection site in human protein kinase CK2alpha-subunit Hybrid. Hybridomics 22 2003 87 90
28. U. Kuckländer, R. Bollig, W. Frank, A. Gratz, and J. Jose A novel application of DDQ as electrophile in the Nenitzescu reaction Bioorg. Med. Chem. 19 2011 2666 2674
29. M.A. Pagano, M. Andrzejewska, M. Ruzzene, S. Sarno, L. Cesaro, J. Bain, M. Elliott, F. Meggio, Z. Kazimierczuk, and L.A. Pinna Optimization of protein kinase CK2 inhibitors derived from 4,5,6,7-tetrabromobenzimidazole J. Med. Chem. 47 2004 6239 6247
30. G. Cozza, M. Mazzorana, E. Papinutto, J. Bain, M. Elliott, M.G. Di, A. Gianoncelli, M.A. Pagano, S. Sarno, M. Ruzzene, R. Battistutta, F. Meggio, S. Moro, G. Zagotto, and L.A. Pinna Quinalizarin as a potent, selective and cell-permeable inhibitor of protein kinase CK2 Biochem. J. 421 2009 387 395
31. R.A. Copeland Evaluation of enzyme inhibitors in drug discovery. A guide for medicinal chemists and pharmacologists Methods Biochem. Anal. 46 2005 1 265
32. P. Cohen Protein kinases - the major drug targets of the twenty-first century? Nat. Rev. Drug Discov. 1 2002 309 315
33. B. Laudet, V. Moucadel, R. Prudent, O. Filhol, Y.S. Wong, D. Royer, and C. Cochet Identification of chemical inhibitors of protein-kinase CK2 subunit interaction Mol. Cell. Biochem. 316 2008 63 69
34. E. Buchdunger, C.L. Cioffi, N. Law, D. Stover, S. Ohno-Jones, B.J. Druker, and N.B. Lydon Abl protein-tyrosine kinase inhibitor STI571 inhibits in vitro signal transduction mediated by c-kit and platelet-derived growth factor receptors J. Pharmacol. Exp. Ther. 295 2000 139 145
35. J.S. Horoszewicz, S.S. Leong, T.M. Chu, Z.L. Wajsman, M. Friedman, L. Papsidero, U. Kim, L.S. Chai, S. Kakati, S.K. Arya, and A.A. Sandberg The LNCaP cell line - a new model for studies on human prostatic carcinoma Prog. Clin. Biol. Res. 37 1980 115 132
36. S. Sarno, M. Ruzzene, P. Frascella, M.A. Pagano, F. Meggio, A. Zambon, M. Mazzorana, G. Di Maira, V. Lucchini, and L.A. Pinna Development and exploitation of CK2 inhibitors Mol. Cell. Biochem. 274 2005 69 76
37. J.P. van Brussel, G.J. van Steenbrugge, J.C. Romijn, F.H. Schroder, and G.H. Mickisch Chemosensitivity of prostate cancer cell lines and expression of multidrug resistance-related proteins Eur. J. Cancer 35 1999 664 671
38. S. Tawfic, S. Yu, H. Wang, R. Faust, A. Davis, and K. Ahmed Protein kinase CK2 signaling in neoplasia Histol. Histopathol. 16 2001 573 582
39. M. Koronkiewicz, M. Zukowska, Z. Chilmonczyk, A. Orzeszko, and Z. Kazimierczuk Synthesis and proapoptotic properties of new casein kinase II inhibitors Acta Pol. Pharm. 67 2010 635 641
40. M.A. Pagano, J. Bain, Z. Kazimierczuk, S. Sarno, M. Ruzzene, G. Di Maira, M. Elliott, A. Orzeszko, G. Cozza, F. Meggio, and L.A. Pinna The selectivity of inhibitors of protein kinase CK2. An update Biochem. J. 415 2008 353 365
41. K.B. Lukasiewicz, and W.L. Lingle Aurora A, centrosome structure, and the centrosome cycle Environ. Mol. Mutagen. 50 2009 602 619
42. F. Lang, N. Perrotti, and C. Stournaras Colorectal carcinoma cells - regulation of survival and growth by SGK1 Int. J. Biochem. Cell Biol. 42 2010 1571 1575
43. M.J. Karkkainen, and T.V. Petrova Vascular endothelial growth factor receptors in the regulation of angiogenesis and lymphangiogenesis Oncogene 19 2000 5598 5605
44. N.S. Magnuson, Z. Wang, G. Ding, and R. Reeves Why target PIM1 for cancer diagnosis and treatment? Future Oncol. 6 2010 1461 1478
45. G. Manning, D.B. Whyte, R. Martinez, T. Hunter, and S. Sudarsanam The protein kinase complement of the human genome Science 298 2002 1912 1934